Rockwell Medical, Inc.

RMTI

$8.05

-0.25%

2026-09-03 12:03:00 EDT-$0.02

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. ...

Price Action of RMTI

$8.05

-0.25%-$0.02

High—

Low—

52W High-56.4%

Rel. vol—

Interval

Range4.7h

Volume—SMA5SMA10

—

Rockwell Medical, Inc. is a fully-integrated biopharmaceutical company focused on treatments for chronic and end-stage kidney disease. Established in 1996 and headquartered in Wixom, Michigan, the company specializes in both innovative iron replacement therapies and essential hemodialysis products. Its key product line, Triferic (including Triferic Dialysate and Triferic AVNU), is ...Rockwell Medical, Inc. is a fully-integrated biopharmaceutical company focused on treatments for chronic and end-stage kidney disease. Established in 1996 and headquartered in Wixom, Michigan, the company specializes in both innovative iron replacement therapies and essential hemodialysis products. Its key product line, Triferic (including Triferic Dialysate and Triferic AVNU), is an iron replacement therapy designed to maintain hemoglobin levels in dialysis patients without increasing iron stores. Beyond this, Rockwell Medical manufactures and distributes a comprehensive range of hemodialysis concentrates, including acid concentrates (CitraPure, Dri-Sate, RenalPure) and powder bicarbonate concentrates (RenalPure, SteriLyte), which are crucial for removing toxins and replacing essential nutrients in patients' blood. The company also supplies ancillary items such as blood tubing, fistula needles, dialyzers, dressings, and cleaning agents. Rockwell Medical primarily serves medium and small-sized dialysis chains and independent dialysis centers, aiming to become a leading global supplier of hemodialysis concentrates. The company is actively developing additional therapeutic candidates for acute heart failure and home infusion therapy. With a workforce of approximately 157 employees, Rockwell Medical has a strong focus on long-term growth and innovation, positioning itself as a key player in the dialysis market. Its operations span both domestic and international markets, supported by a dedicated team and a commitment to quality and life-sustaining solutions.ExpandCollapse

Founded

1996

Employees

157

CEO

Mark Strobeck

Full Name

Rockwell Medical, Inc.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

ROE

-14.03%

Market Cap

$0.03B

Current Ratio

3.25

WACC

11.24%

ROIC

-8.82%

Contact Information

https://www.rockwellmed.com

248 960 9009

30142 South Wixom road, Wixom, MI 48393

Key Metrics of RMTI

Snapshot

Latest / TTM · 6 periods

Market Cap

$31.77M

ROCE

-10.0%

EV / EBITDA

-15.04x

-0.1% YoY

FCF Yield

4.8%

+8.8% YoY

Cash Conversion Cycle

41.4d

Current Ratio

3.25

Quick take

TTM —

Positive CCC

Financial Highlights of RMTI

Profitability trend

Latest / TTM · 6 periods

Gross Margin

17.7%

Net Margin

-7.3%

P/E Ratio

-5.79x

n/a

Debt / Equity

0.40

n/a

Current Ratio

3.25

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of RMTI

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.18 · Revenue $18.27M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.10 · Revenue $19.07M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.94 · Revenue $72.49M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.13 · Revenue $18.85M · 1 analysts

Recent history

Aug 13, 2026
Q2 FY2026 · Results reported
EPS $-0.34 · Revenue $17.78M
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $-0.41 · Revenue $17.34M
View filing
Mar 26, 2026
FY2025 · Annual results
EPS $-1.50 · Revenue $69.26M
View filing
Nov 12, 2025
Q3 FY2025 · Results reported
EPS $-0.50 · Revenue $15.93M
View filing
Aug 14, 2025
Q2 FY2025 · Results reported
EPS $-0.43 · Revenue $16.07M
View filing
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-0.44 · Revenue $18.91M

Financial Statements of RMTI

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$69.3M	-31.8%	+2.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-5.3M	-1007.1%	+27.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+16.9%	-2.0%	+9.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-6.8%	-1230.6%	+30.1%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-7.7%	-1522.3%	+28.8%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-1.2M	-137.6%	+347.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-1.7%	-155.2%	+341.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	33.7%	-18.8%	-1.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	3.98x	+51.6%	-13.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$57.1M	-3.5%	-1.6%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.50 vs -1.15	-30.4%	-0.34 vs -0.23	-44.7%
Revenue Surprise	$69.3M vs $69.5M	-0.4%	$17.8M vs $17.8M	-0.2%

Insider Transactions of RMTI

Acquisitions (A)

Since Jul 1, 2026

Disposals (D)

Since Jul 1, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 1, 2026	Dawson Joseph H	director	Common Stock	A	9,633	—
Jul 1, 2026	Nissenson Allen	director	Common Stock	A	9,633	—
Jul 1, 2026	Lau Joan	director	Common Stock	A	9,633	—
Jul 1, 2026	Radie Robert S	director	Common Stock	A	9,633	—
Jul 1, 2026	COOPER JOHN G	director	Common Stock	A	9,633	—

Earnings Call Transcript of RMTI

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Thank you. Good morning and welcome to Rockwell Medical's second quarter 2026 results conference call and webcast. Please note, this event is being recorded. At this time, I would like to turn the conference call over to Heather Hunter, Chief Operating Officer at Rockwell Medical. Heather, please go ahead. Heather Hunter: Good morning, everyone, and thank you for joining us for this update on Rockwell Medical. Joining me on today's conference call are Dr.Mark Strobeck, Rockwell Medical's President and CEO, and Jesse Neri, Rockwell Medical's CFO. Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as this concept is required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in, or implied by, such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. Rockwell Medical's quarterly report on Form 10-Q for the 3 months ended June 30, 2026, was filed prior to this call and provides a full analysis of the company's business strategy, as well as the company's second quarter 2026 results. The reconciliation of non-GAAP measures we discuss on today's call can also be found in today's press release. Our Form 10-Q and other reports filed with the SEC along with today's press release, our updated investor presentation, and a replay of today's call can be found on our website under the investor section. Now I will turn the call over to Rockwell Medical's President and CEO, Dr. Mark Strobeck. Mark Strobeck: Thank you, Heather, and good morning, everyone. Thank you for joining us today on Rockwell Medical's second quarter 2026 earnings conference call and webcast. The second quarter was another important step forward for Rockwell Medical. We delivered strong year-over-year growth, continued to expand gross margin, generated positive operating cash flow, strengthened our customer portfolio, and advanced the operational initiatives that we believe will continue to drive long-term shareholder value. As a result, we remain on track to achieve our full-year 2026 guidance while continuing to execute against our strategy for further growth in the years ahead. When I think about where Rockwell is today compared to just a few years ago, the difference is significant. Our focus over the last several years has been …

Leadership Team of RMTI

6 executives

Name	Title	Compensation	Gender	Year Born	Status
Mark Strobeck	President, Chief Executive Officer & Director	USD 1,033,700	—	1971	Active
Megan C. Timmins	Executive Vice President, Chief Legal Officer & Secretary	USD 611,400	Female	1973	Active
Jesse Neri	Senior Vice President & Chief Financial Officer	USD 462,050	Male	1978	Active
Nicholas Fanslau	Controller & Principal Accounting Officer	—	Male	1985	Active
Timothy T. Chole	Senior Vice President & Chief Commercial Officer	—	Male	1974	Active
Heather H. Hunter	Senior Vice President & Chief Operating Officer	—	Female	1979	Active

Recent News of RMTI

Seeking Alpha8/13/2026Neutral

Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript

Zacks Investment Research8/13/2026Neutral

Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates

Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.

GuruFocus8/13/2026Neutral

Rockwell Medical Announces Second Quarter 2026 Results

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodial

Business Wire8/13/2026Neutral

Rockwell Medical Announces Second Quarter 2026 Results

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces Q2'26 results, delivering strong year-over-year growth, expanding gross margin and generating positive operating cash flow.

Zacks Investment Research8/6/2026Neutral

Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Historical Employee Count of RMTI

Current

157

Change

-35.66%

Minimum

157

Maximum

300

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	157	10-K	Mar 26, 2026	View
Dec 31, 2024	244	10-K	Mar 20, 2025	View
Dec 31, 2023	237	10-K	Mar 21, 2024	View
Dec 31, 2022	253	10-K	Mar 30, 2023	View
Dec 31, 2021	300	10-K	Apr 8, 2022	View

Related stocksDrug Manufacturers - Specialty & Generic

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Rockwell Medical, Inc.